Abstract： Objective To investigate the effects of sacubitril valsartan on ventricular remodeling and the level of N-terminal B-type brain natriuretic peptide(NT-proBNP)in patients with acute decompensated ejection fraction reduction in heart failure.Methods A total of 60 patients with acute decompensated heart failure with reduced ejection fraction admitted to Xinjian District People's Hospital from January 2021 to August 2022 were selected as the study objects.They were divided into group A(30 cases)and group B(30 cases)by random number table.All patients received conventional treatment,on this basis,group A was treated with valsartan and group B was treated with sacubitril valsartan,continuous treatment for 3 months.The efficacy,cardiac function indexes[left ventricular end-diastolic diameter(LVEDd),left ventricular ejection fraction(LVEF),left ventricular posterior wall thickness(LVPW)],resting hemodynamics[heart rate(HR),systolic blood pressure(SBP)],serological indexes of myocardial function injury[cardiac troponin Ⅰ(cTnⅠ),NT-proB]before and after treatment,Hypersensitive C-reactive protein(hs-CRP)],adverse reactions were evaluated.Results The treatment effective rate of group B was higher than that of group A,the difference was statistically significant(P＜0.05).There was no significant difference in LVEDd,LVEF,LVPW,resting HR,SBP,cTnⅠ,NT-proBNP and hs-CRP levels between the two groups before treatment(P＞0.05).After treatment,LVEDd level in group B was lower than that in group A,LVEF level was higher than that in group A,the level of resting HR in group B was lower than that in group A,the level of SBP was higher than that in group A,the levels of cTnⅠ,NT-proBNP and hs-CRP in group B were lower than those in group A,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion On the basis of conventional treatment for patients with acute decompensated ejection fraction reduction in heart failure,compared with valsartan treatment,the application of sacubitril valsartan can improve the therapeutic effect,inhibit ventricular remodeling,improve hemodynamic indexes,alleviate myocardial function injury,and do not increase the adverse effects of treatment.